FIA
CYTK icon

FNY Investment Advisers’s Cytokinetics CYTK Stock Holding History

FNY Investment Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33
Closed -$1K – 1038
2025
Q3 		$1K Hold
33
– – ﹤0.01% 1124
2025
Q2 		$1K Buy
+33
New +$1.15K ﹤0.01% 887
2025
Q1 		– Sell
-255
Closed -$11K – 772
2024
Q4 		$11K Buy
+255
New +$13.2K 0.01% 481
2024
Q1 		– Sell
-30
Closed -$2K – 703
2023
Q4 		$2K Buy
+30
New +$1.09K ﹤0.01% 394

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

FNY Investment Advisers's CYTK Position: Q2 2026 in Review

FNY Investment Advisers reduced its Cytokinetics (CYTK) stake by 78% in Q2 2026, selling an estimated $505K and leaving 2,000 shares worth $170K. The position accounts for 0.06% of the portfolio, ranked #260.

FNY Investment Advisers first reported a position in CYTK in Q1 2024 and has held it in 10 quarters since. The position peaked at $684K in Q4 2024. 269 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • FNY Investment Advisers held 2,000 shares of Cytokinetics worth $170K as of Q2 2026.
  • FNY Investment Advisers sold 7,030 Cytokinetics shares in Q2 2026, an estimated $505K.
  • Cytokinetics made up 0.06% of FNY Investment Advisers's portfolio in Q2 2026, its #260 holding.
  • FNY Investment Advisers first reported a position in Cytokinetics in Q1 2024 and has held it in 10 quarters since.
  • FNY Investment Advisers's Cytokinetics position peaked at $684K in Q4 2024.
  • 269 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.